Osteoarthritis development is induced by increased dietary cholesterol and can be inhibited by atorvastatin in APOE*3Leiden.CETP mice-a translational model for atherosclerosis

Annals of the Rheumatic Diseases

Volumn 73, Issue 5, 2014, Pages 921-927

  Gierman, L M ^a,b   Kuhnast S ^a,b   Koudijs, A ^a   Pieterman, E J ^a   Kloppenburg, M ^b   Van Osch, G J V M ^c   Stojanovic Susulic, V ^d   Huizinga, T W J ^b   Princen, H M G ^a   Zuurmond, A M ^a  

^a TNO   (Netherlands)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^c ERASMUS MEDICAL CENTER   (Netherlands)

^d Biologics Clinical Pharmacology   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; APOLIPOPROTEIN E; ATORVASTATIN; CHOLESTEROL ESTER TRANSFER PROTEIN; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; EZETIMIBE; MONOCYTE CHEMOTACTIC PROTEIN 1; SERUM AMYLOID A; VERY LOW DENSITY LIPOPROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ATHEROSCLEROSIS; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL INTAKE; CONTROLLED STUDY; FEMALE; KNEE OSTEOARTHRITIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; TRANSGENIC MOUSE;

ATHEROSCLEROSIS; INFLAMMATION; LIPIDS; OSTEOARTHRITIS;

ANIMALS; ANTICHOLESTEREMIC AGENTS; APOLIPOPROTEIN E3; ATHEROSCLEROSIS; CHOLESTEROL ESTER TRANSFER PROTEINS; CHOLESTEROL, DIETARY; DISEASE MODELS, ANIMAL; HEPTANOIC ACIDS; HUMANS; HYPERCHOLESTEROLEMIA; MICE; MICE, TRANSGENIC; OSTEOARTHRITIS; PYRROLES;

EID: 84898769338     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/annrheumdis-2013-203248     Document Type: Article

References (43)

1. Dahaghin S, Bierma-Zeinstra SM, Koes BW, et al. Do metabolic factors add to the effect of overweight on hand osteoarthritis? The Rotterdam Study. Ann Rheum Dis 2007;66:916-20. (Pubitemid 46999793)
2. Katz JD, Agrawal S, Velasquez M. Getting to the heart of the matter: osteoarthritis takes its place as part of the metabolic syndrome. Curr Opin Rheumatol 2010;22:512-9.
3. Velasquez MT, Katz JD. Osteoarthritis: another component of metabolic syndrome? Metab Syndr Relat Disord 2010;8:295-305.
4. Day C. Metabolic syndrome, or What you will: definitions and epidemiology. Diab Vasc Dis Res 2007;4:32-8. (Pubitemid 46649071)
5. Puenpatom RA, Victor TW. Increased prevalence of metabolic syndrome in individuals with osteoarthritis: an analysis of NHANES III data. Postgrad Med 2009;121:9-20.
6. Sturmer T, Sun Y, Sauerland S, et al. Serum cholesterol and osteoarthritis. The baseline examination of the Ulm Osteoarthritis Study. J Rheumatol 1998;25:1827-32. (Pubitemid 28439280)
7. Davies-Tuck ML, Hanna F, Davis SR, et al. Total cholesterol and triglycerides are associated with the development of new bone marrow lesions in asymptomatic middle-aged women - a prospective cohort study. Arthritis Res Ther 2009;11:R181.
8. Kleemann R, Verschuren L, van Erk MJ, et al. Atherosclerosis and liver inflammation induced by increased dietary cholesterol intake: a combined transcriptomics and metabolomics analysis. Genome Biol 2007;8:R200.
9. Tannock LR, O'brien KD, Knopp RH, et al. Cholesterol feeding increases C-reactive protein and serum amyloid A levels in lean insulin-sensitive subjects. Circulation 2005;111:3058-62. (Pubitemid 40847782)
10. Gierman LM, van der Ham F, Koudijs A, et al. Metabolic stress-induced inflammation plays a major role in the development of osteoarthritis in mice. Arthritis Rheum 2012;64:1172-81.
11. Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med 2005;352:1685-95.
12. Libby P, Ridker PM, Maseri A. Inflammation and atherosclerosis. Circulation 2002;105:1135-43. (Pubitemid 34212626)
13. Gkretsi V, Simopoulou T, Tsezou A. Lipid metabolism and osteoarthritis: lessons from atherosclerosis. Prog Lipid Res 2011;50:133-40.
14. Hoeven TA, Kavousi M, Clockaerts S, et al. Association of atherosclerosis with presence and progression of osteoarthritis: the Rotterdam Study. Ann Rheum Dis 2013;72:646-51.
15. Jonsson H, Helgadottir GP, Aspelund T, et al. Hand osteoarthritis in older women is associated with carotid and coronary atherosclerosis: the AGES Reykjavik study. Ann Rheum Dis 2009;68:1696-700.
16. Conaghan PG, Vanharanta H, Dieppe PA. Is progressive osteoarthritis an atheromatous vascular disease? Ann Rheum Dis 2005;64:1539-41. (Pubitemid 41532034)
17. Gotto AM Jr, Moon JE. Recent clinical studies of the effects of lipid-modifying therapies. Am J Cardiol 2012;110:15A-26A.
18. Clockaerts S, Van Osch GJ, Bastiaansen-Jenniskens YM, et al. Statin use is associated with reduced incidence and progression of knee osteoarthritis in the Rotterdam study. Ann Rheum Dis 2012;71:642-7.
19. Akasaki Y, Matsuda S, Iwamoto Y. Progress of research in osteoarthritis. The anti-inflammatory effects of intra-articular injected statin on experimental osteoarthritis. Clin Calcium 2009;19:1653-62.
20. Akasaki Y, Matsuda S, Nakayama K, et al. Mevastatin reduces cartilage degradation in rabbit experimental osteoarthritis through inhibition of synovial inflammation. Osteoarthritis Cartilage 2009;17:235-43.
21. Westerterp M, van der Hoogt CC, de Haan W, et al. Cholesteryl ester transfer protein decreases high-density lipoprotein and severely aggravates atherosclerosis in APOE*3-Leiden mice. Arterioscler Thromb Vasc Biol 2006;26:2552-9. (Pubitemid 44607480)
22. Delsing DJ, Offerman EH, van Duyvenvoorde W, et al. Acyl-CoA:cholesterol acyltransferase inhibitor avasimibe reduces atherosclerosis in addition to its cholesterol-lowering effect in ApoE*3-Leiden mice. Circulation 2001;103:1778-86. (Pubitemid 32291416)
23. Kleemann R, Princen HM, Emeis JJ, et al. Rosuvastatin reduces atherosclerosis development beyond and independent of its plasma cholesterol-lowering effect in APOE*3-Leiden transgenic mice: evidence for antiinflammatory effects of rosuvastatin. Circulation 2003;108:1368-74. (Pubitemid 37174416)
24. de Haan W, de Vries-van der Weij J, van der Hoorn JWA, et al. Torcetrapib does not reduce atherosclerosis beyond atorvastatin and induces more proinflammatory lesions than atorvastatin. Circulation 2008;117:2515-22. (Pubitemid 351670459)
25. Kuhnast S, van der Hoorn JWA, van den Hoek AM, et al. Aliskiren inhibits atherosclerosis development and improves plaque stability in APOE*3Leiden.CETP transgenic mice with or without treatment with atorvastatin. J Hypertens 2012;30:107-16.
26. van der Hoogt CC, de Haan W, Westerterp M, et al. Fenofibrate increases HDL-cholesterol by reducing cholesteryl ester transfer protein expression. J Lipid Res 2007;48:1763-71. (Pubitemid 47311993)
27. van der Hoorn JW, de Haan W, Berbee JF, et al. Niacin increases HDL by reducing hepatic expression and plasma levels of cholesteryl ester transfer protein in APOE*3Leiden.CETP mice. Arterioscler Thromb Vasc Biol 2008;28:2016-22.
28. Westerterp M, Koetsveld J, Tall AR. Cholesteryl Ester transfer protein inhibition: a dysfunctional endothelium. J Cardiovasc Pharmacol 2010;55:456-8.
29. Kristensen HK. An improved method of decalcification. Stain Technol 1948;23:151-4.
30. Glasson SS, Van Chambers MG, et al. The OARSI histopathology initiative - recommendations for histological assessments of osteoarthritis in the mouse. Osteoarthritis Cartilage 2010;18(Suppl 3):S17-23.
31. Pritzker KP, Gay S, Jimenez SA, et al. Osteoarthritis cartilage histopathology: grading and staging. Osteoarthritis Cartilage 2006;14:13-29. (Pubitemid 43034086)
32. Stary HC, Chandler AB, Dinsmore RE, et al. A definition of advanced types of atherosclerotic lesions and a histological classification of atherosclerosis. A report from the Committee on Vascular Lesions of the Council on Arteriosclerosis, American Heart Association. Arterioscler Thromb Vasc Biol 1995; 15:1512-31.
33. Masuko K, Murata M, Suematsu N, et al. A metabolic aspect of osteoarthritis: lipid as a possible contributor to the pathogenesis of cartilage degradation. Clin Exp Rheumatol 2009;27:347-53.
34. Yoshimura N, Muraki S, Oka H, et al. Association of knee osteoarthritis with the accumulation of metabolic risk factors such as overweight, hypertension, dyslipidemia, and impaired glucose tolerance in Japanese men and women: the ROAD study. J Rheumatol 2011;38:921-30.
35. Griffin TM, Huebner JL, Kraus VB, et al. Induction of osteoarthritis and metabolic inflammation by a very high-fat diet in mice: effects of short-term exercise. Arthritis Rheum 2012;64:443-53.
36. Griffin TM, Guilak F. Why is obesity associated with osteoarthritis? Insights from mouse models of obesity. Biorheology 2008;45:387-98.
37. Griffin TM, Fermor B, Huebner JL, et al. Diet-induced obesity differentially regulates behavioral, biomechanical, and molecular risk factors for osteoarthritis in mice. Arthritis Res Ther 2010;12:R130.
38. McNulty MA, Loeser RF, Davey C, et al. Histopathology of naturally occurring and surgically induced osteoarthritis in mice. Osteoarthritis Cartilage 2012;20:949-56.
39. Tsezou A, Iliopoulos D, Malizos KN, et al. Impaired expression of genes regulating cholesterol efflux in human osteoarthritic chondrocytes. J Orthop Res 2010;28:1033-9.
40. Tabas I. Consequences of cellular cholesterol accumulation: basic concepts and physiological implications. J Clin Invest 2002;110:905-11.
41. Kostopoulou F, Gkretsi V, Malizos KN, et al. Central role of SREBP-2 in the pathogenesis of osteoarthritis. PLoS ONE 2012;7:e35753.
42. Goldring MB, Otero M. Inflammation in osteoarthritis. Curr Opin Rheumatol 2011;23:471-8.
43. Ray KK, Cannon CP, Ganz P. Beyond lipid lowering: What have we learned about the benefits of statins from the acute coronary syndromes trials? Am J Cardiol 2006;98:18-25.